insights_auto
Why is 4142 down 6,62%?
Dive Deeperchevron_right
4142:TPE
Adimmune Corp
14,80 NT$
arrow_downward
-6,62%(-1,05) 1D
20 նոյ, 13:30:09 GMT+8 · TWD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4142...
Open
15,75 NT$
High
15,75 NT$
Low
14,80 NT$
Mkt. cap
6,36 մլրդ
Avg. vol.
1,13 մլն
Volume
1,63 մլն
P/E ratio
85,76
52-wk high
21,50 NT$
52-wk low
14,80 NT$
EPS
0,17 NT$
Shares outstanding
235,29 մլն
No. of employees
564
Open
15,75 NT$
High
15,75 NT$
Low
14,80 NT$
Mkt. cap
6,36 մլրդ
Avg. vol.
1,13 մլն
Volume
1,63 մլն
P/E ratio
85,76
52-wk high
21,50 NT$
52-wk low
14,80 NT$
EPS
0,17 NT$
Shares outstanding
235,29 մլն
No. of employees
564
News stories
From web sources and news partners
24/7 Wall St.
·
1 ժամ առաջ
Billionaire Ray Dalio's Bridgewater Keeps 16% of Its $23 Billion Stock Portfolio in S&P 500 Index Funds, Even After Cutting Them
Crypto Briefing
·
2 ժամ առաջ
Nasdaq slides deeper as Nvidia rout drags S&P 500 and Dow into correction
Traders Union
·
3 ժամ առաջ
Ryan Detrick: S&P 500 rose after seven-day losing streak in 16 out of 17 years since 1978
TradingView
·
4 ժամ առաջ
Yardeni Trims S&P 500 Year-End Forecast Again, Says Bear Market Is Unlikely
Profile
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
About Adimmune Corp